Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer

IMPORTANCE: Trastuzumab is life-saving but is associated with symptomatic and asymptomatic left ventricular ejection fraction (LVEF) decline. Here we report the low cardiac toxicity of a non-anthracycline and trastuzumab based treatment for patients with early stage HER2-positive breast cancer (BCA)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Dang, Chau, Guo, Hao, Najita, Julie, Yardley, Denise, Marcom, Kelly, Albain, Kathy, Rugo, Hope, Miller, Kathy, Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Moy, Beverly, Groarke, John, Moslehi, Javid, Krop, Ian, Burstein, Harold J., Hudis, Clifford, Winer, Eric P., Tolaney, Sara M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5654518/
https://ncbi.nlm.nih.gov/pubmed/26539793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.3709
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados